PV-0512: Accelerated partial breast irradiation for Luminal-A breast cancer: analysis from a phase 3 trial  by Meattini, I. et al.
S242                                                                                     ESTRO 35 2016 
 _____________________________________________________________________________________________________ 
cosmetic outcome was good/excellent in 94% of patients. At 
one year skin toxicity was G1 in 13% of patients, 1 patient 
G2, 1 patient G3; cosmetic outcome was good/excellent in 
93% of patients.After an early evaluation of clinical outcomes 
we have found 12 cases of progression disease, only one 
patient had an In-Breast-Recurrence. 
 
Conclusion: The 3-week course of postoperative radiation 
using VMAT with SIB was well tolerated in acute and early 
late settings. Long-term follow-up data are needed to assess 
late toxicity and clinical outcomes. 
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Purpose or Objective: Breast cancer (BC) could be classified 
into four major molecular subtypes: Luminal-A, Luminal-B, 
triple negative/basal-like, human epidermal growth factor 2 
(HER2) enriched. This classification could be based on 
immunohistochemistry, and may allow the clinicians to 
optimize treatment management. Luminal-A tumors 
represent around 40% of BC and are characterized by: 
estrogen receptor (ER) and/or progesterone receptor (PgR) 
positive, HER2/neu negative, and low Ki-67 proliferative 
index. Early luminal-A tumors tend to have an excellent 
prognosis, with high survival and low recurrence rates. The 
aim of this analysis was to observe Luminal-A outcome from a 
phase 3 trial comparing whole-breast irradiation (WBI) to 
accelerated partial breast irradiation (APBI) using intensity-
modulated radiotherapy (IMRT) technique. 
 
Material and Methods: In the whole trial 520 patients were 
randomized in 1:1 ratio to receive APBI versus WBI after 
breast conserving surgery for early BC. The primary endpoint 
was occurrence of ipsilateral breast tumor recurrence (IBTR); 
the main analysis was by intention-to-treat. This trial was 
registered with ClinicalTrials.gov, number NCT02104895. 
 
Results: Luminal-A patients represented the 61.5% of the 
whole series (151 WBI versus 169 APBI). 5-year event rate 
according to allocated group showed no statistical difference 
in terms of IBTR (p=0.53). One case (0.9%) versus two cases 
(1.7%) were observed in the WBI and APBI arms, respectively. 
Survival events occurrences and IBTR curve are summarized 
in the Figures. 
 
 
 
 
Conclusion: We observed a very low 5-year rate of IBTR for 
Luminal-A patients treated with APBI. Although these results 
should be confirmed at a longer follow up time, this approach 
should be considered for this subset of early BC patients. 
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Purpose or Objective: To evaluate toxicity in breast cancer 
patients treated with anthracycline and taxane based 
chemotherapy and whole breast hypofractionated 
radiotherapy, and to identify the risk factors for toxicity. 
 
Material and Methods: From April 2009 to December 2014, 
540 patients received radiotherapy after breast conservative 
surgery (BCS). The dose was 42.4 Gy in 16 daily fractions, 
2.65 Gy per fraction. The boost to the tumor bed was 
administered only in grade 3 patients and in patients with 
close or positive margins. Acute and late toxicity were 
prospectively assessed during and after radiotherapy 
according to RTOG scale. The impact of patients clinical 
characteristics and dose inhomogeneities on the occurrence 
of an higher level of toxicity has been also evaluated by 
univariate and multivariate analysis. 
 
Results: One hundred and nineteen patients received 
chemotherapy. Sixty-one patients (11.3%) underwent 
trastuzumab therapy and four hundred and forty-one (81.6%) 
hormonotherapy. The mean age was 74 (range 46-91 yrs). 
Forty seven (8.7%) and two hundred fifty eight (47.5%) 
patients were affected by diabetes mellitus and 
hypertension, respectively. G1 and G2/G3 acute skin toxicity 
were 53.7% and 28.5% in patients received chemotherapy and 
63.2% and 18.5% in patients who did not receive it, 
respectively. No significant difference (p=0.092) was find 
